Advertisement

An Overview of Biochemical and Clinical Research on Coenzyme Q with Emphasis on Cardiomyopathy and Muscle Dystrophy

  • Karl Folkers
  • Teresa Lyson
  • Krzysztof Lyson
  • Kasumasa Muratsu
  • Rodney Simonsen
  • Per Langsjoen

Abstract

I am very pleased to be a participant in this Colloquium in honor of Dr. Tsoo King. This Colloquium on Membrane Biochemistry and Bioenergetics is a very nice tribute to Dr. King for his career of accomplishments. Since Dr. King invited me to present an overview, I include a little nostalgia, but I wish to emphasize some new data on the survival rates of patients with advanced cardiomyopathy when they are treated with coenzyme Q10 (CoQ10) in addition to conventional therapy. Also, I shall emphasize some new data on treating patients with muscle dystrophy with CoQ10. The new therapy of muscle dystrophy with CoQ10 is the only known therapy which offers a better quality of life to such patients. This disease appears to be ideal for combining the biochemical and clinical aspects of CoQ10, and particularly because of the new availability of phosphorus NMR as currently studied by Britton Chance and other investigators. Phosphorus NMR allows the determinations of tissue levels of phosphocreatine, P1, and ATP with accuracy.

Keywords

Myotonic Dystrophy Muscle Dystrophy Tooth Disease Muscular Disease Quinone Pool 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Crane, F.L. (1986) in: Biomedical and Clinical Aspects of Coenzyme Q. (Folkers, K.,and Yamamura, Y. eds.) Vol. 5, 3–14, Elsevier Science Publishers, B.V.:New YorkGoogle Scholar
  2. 2.
    Beyer, R.E., Nordenbrand, K.,and Ernster, L., (1986) in: Biomedical and Clinical Aspects of Coenzyme Q. (Folkers, K.,and Yamamura, Y., eds.) Vol. 5., 17–24, Elsevier Science Publishers B.V.: New YorkGoogle Scholar
  3. 3.
    Furberg, C.D., and Yusuf, S., Am. J. Cardiol. (1985) 55, 1110–1113CrossRefGoogle Scholar
  4. 4.
    Colussi, W.S., Wright, R.F., and Braunwald, E.(1986) NEJM, 314, 349–358CrossRefGoogle Scholar
  5. 5.
    Carafoli, E., and Roman, I. (1980) Mol. Aspects Med. 3, 295CrossRefGoogle Scholar
  6. 6.
    Morgan-Hughes, J.A., (1983) in: Advanced Medicine (Saunders, K.B., ed) 19, 243–260, Pitman: LondonGoogle Scholar
  7. 7.
    Morgan-Hughes, J.A., Hayes, D.J., Clark, J.B., and Cooper, J.M. (1984) in. Biomedical and Clinical Aspects of Coenzyme Q. (Folkers, K., and Yamamura, Y., eds.) Vol. 4, 417–424, Elsevier Science Publishers B.V.:New YorkGoogle Scholar
  8. 8.
    Schölte, H.R., Luyt-Houwen, I.E.M., Busch, H.F.M., and Vaandrager-Verduin, M.H. (May 1986) New York Academy of Sciences, Como Meeting Google Scholar
  9. 9.
    Duboc, D., Jehenson, P., Tran Dinh, S., Syrota, A., and Fardeau, M., (1986) VJ Internat. Congress on Neuromusclar Disease in Los AngelesGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Karl Folkers
    • 1
  • Teresa Lyson
    • 1
  • Krzysztof Lyson
    • 1
  • Kasumasa Muratsu
    • 1
  • Rodney Simonsen
    • 1
  • Per Langsjoen
    • 1
    • 2
  1. 1.Institute for Biomedical ResearchThe University of Texas at AustinAustinUSA
  2. 2.Department of MedicineDivision of Cardiology Scott and White ClinicTempleUSA

Personalised recommendations